RECENT FUNDING
  1. Recent Funding
  2. Companies
  3. Desentum

Desentum

Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

Latest funding

$31.31M ·

Led by Springvest · Source: european-biotechnology.com

Funding history ↓
Website: desentum.fi.
X: @desentumAIT · 56 followers.
LinkedIn: linkedin.com.
Category: Health and bio.
Sectors: Biotechnology, Pharmaceutical.
Based in: Espoo, Finland.
Last round: Oct 12, 2026 · 11 days ago.
X account age: 9 years.
Domain age: 13 years.
On Recent Funding since: Oct 15, 2026.
About Desentum

Desentum is a company based in Espoo, Finland. Recent Funding lists it under Health and bio. It raised $31.31M in a funding round in October 2026, led by Springvest, according to european-biotechnology.com. Investors on record include Cascara Ventures, European Innovation Council Fund, Luxembourgian ACME Investments, Sto-Rahoitus and 1 other. It was founded by Pekka Mattila.

Funding rounds

  1. Round · $31.31M
  2. X account created
  3. Website created

Founders and team

Investors

Similar Health and bio companies

Other companies backed by Springvest

Springvest portfolio →

Questions and sources

Desentum: questions and answers

How much has Desentum raised?
Desentum has raised $31.31M in one sourced round on record, announced October 12, 2026.
Who invested in Desentum?
Investors on record for Desentum: Cascara Ventures, European Innovation Council Fund, Luxembourgian ACME Investments, Springvest, Sto-Rahoitus and VTT Ventures. Springvest led its latest sourced round.
Who founded Desentum?
Desentum was founded by Pekka Mattila.
Where is Desentum based?
Desentum is based in Espoo, Finland.

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/desentum (get a free API key).

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy